As the debate over mifepristone makes its way to the Supreme Court, the pharmaceutical industry has raised concerns that ruling against the FDA could chill the development of new drugs.
Prescribing medical abortions across state lines is now risky for doctors. "We're talking about something that's a protected right in one state and a felony in a sister state," says one legal scholar.
